IGF-I, insulin and prostate cancer
IGF-I, insulin and prostate cancer
复制标题
DOI：
10.1590/s0004-27302009000800010
复制
发表时间：
2009-11-01
期刊：
影响因子：
--
通讯作者：
Gadelha, Mônica R.
中科院分区：
文献类型：
--
作者：
Lima, Giovanna A. Balarini;Corrêa, Lívia L.;Gadelha, Mônica R.
前列腺癌是成年男性中第二常见的恶性肿瘤。雄激素被认为是前列腺正常细胞和癌细胞的主要生长因子。然而，其他非雄激素生长因子也参与了前列腺癌细胞的生长调节。igf - 1与前列腺癌风险之间的关系已得到充分证实。然而，没有证据表明，测量igf - 1比血清前列腺特异性抗原（PSA）水平更能提高前列腺癌检测的特异性。到目前为止，对于IGFBP-3与前列腺癌风险之间可能存在的联系还没有达成共识。虽然还没有得到很好的证实，但高胰岛素水平似乎与侵袭性前列腺肿瘤的风险特别相关。本文综述了支持IGFs家族和胰岛素与前列腺癌相关的生理病理基础、流行病学证据和动物模型。它还描述了针对这些生长因子的潜在治疗方法，未来可用于治疗前列腺癌患者。中华医学杂志；2009；53 (8): 969 - 75
Prostate cancer is the second most frequent malignancy diagnosed in adult men. Androgens are considered the primary growth factors for prostate normal and cancer cells. However, other non-androgenic growth factors are involved in the growth regulation of prostate cancer cells. The association between IGF-I and prostate cancer risk is well established. However, there is no evidence that the measurement of IGF-I enhances the specificity of prostate cancer detection beyond that achievable by serum prostate-specific antigen (PSA) levels. Until now, there is no consensus on the possible association between IGFBP-3 and prostate cancer risk. Although not well established, it seems that high insulin levels are particularly associated with risk of aggressive prostatic tumours. This review describes the physiopathological basis, epidemiological evidence, and animal models that support the association of the IGFs family and insulin with prostate cancer. It also describes the potential therapies targeting these growth factors that, in the future, can be used to treat patients with prostate cancer. Arq Bras Endocrinol Metalb. 2009;53(8):969-75